Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026
Maternal asthma may raise congenital heart defect risk in offspring
Asthma and allergic tendency in mothers appear to elevate the risk of congenital heart defect (CHD) in their children, suggests a study, noting that nonallergic asthma also contributes to such risk.
Maternal asthma may raise congenital heart defect risk in offspring
15 Jan 2026
EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
